Stem cell therapy for treatment of acute myocardial infarction

The aim of the study is to compare the efficacy of intracoronary infusion of a sorted subpopulation of bone marrow-derived CD34+/CXCR4+ cells versus that of intracoronary infusion of unselected bone marrow-derived mononuclear cells (BM-MNCs) in patients with acute myocardial infarction. There were no differences in major cardiovascular events (death, re-infarction, stroke, target vessel revascularization) between cohorts. In patients with acute myocardial infarction and impaired left ventricular ejection fraction (LVEF), treatment with either selected or non-selected BMCs did not lead to a significant improvement in LVEF volumes. In patients with most severely impaired LVEF, treated with BM-MNCs or bone marrow-derived CD34+/CXCR4+ cells, there was a longer delay between the appearance of myocardial infarction symptoms when compared to untreated patients.